The signs of ocular-surface disorders after switching from latanoprost to tafluprost/timolol fixed combination: a prospective study

Código QR

The signs of ocular-surface disorders after switching from latanoprost to tafluprost/timolol fixed combination: a prospective study

Hideaki Okumichi,1 Yoshiaki Kiuchi,1 Tetsuya Baba,2 Takashi Kanamoto,3 Tomoko Naito,4,5 Shunsuke Nakakura,6 Hitoshi Tabuchi,6 Hiroki Nii,7 Chie Sueoka,7 Yosuke Sugimoto1,8 1Department of Ophthalmology and Visual Science, Graduate School of Biomedical & Health Sciences, Hiroshima University,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Okumichi H, Kiuchi Y, Baba T, Kanamoto T, Naito T, Nakakura S, Tabuchi H, Nii H, Sueoka C, Sugimoto Y
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	tafluprost/timolol fixed combination latanoprost glaucoma ocular-surface safety intraocular pressure Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/9c12189507f54285993c32dd6720882d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Switching from concomitant therapy to tafluprost/timolol fixed combination
por: Inoue K, et al.
Publicado: (2018)

The 24-hour intraocular pressure control by tafluprost/timolol fixed combination after switching from the concomitant use of tafluprost and timolol gel-forming solution, in patients with primary open-angle glaucoma
por: Nakamoto K, et al.
Publicado: (2018)

Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: results of an open-label observational study
por: Pillunat LE, et al.
Publicado: (2017)

Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials
por: Uusitalo H, et al.
Publicado: (2016)

Improved Efficacy of Topical Latanoprost 0.005% Demonstrated by Corneal Biomechanical Correcting Modified Goldmann Prism
por: Radcliffe N, et al.
Publicado: (2020)

Efficacy of the travoprost/timolol fixed combination versus the concomitant use of travoprost 0.004% and timolol 0.1% gel formulation
por: Kozobolis V, et al.
Publicado: (2018)

Comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial
por: Kanamoto T, et al.
Publicado: (2012)

Fixed combination of travoprost and timolol maleate reduces intraocular pressure in Japanese patients with primary open-angle glaucoma or ocular hypertension: analysis by prostaglandin analogue
por: Nakano T, et al.
Publicado: (2016)

Comparison study of intraocular pressure reduction efficacy and safety between latanoprost and tafluprost in Japanese with normal-tension glaucoma
por: Ikeda Y, et al.
Publicado: (2016)

Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice
por: Pfennigsdorf S, et al.
Publicado: (2016)

Comparison of clinical effects of two latanoprost 0.005% solutions (Xalatan® and Arulatan®) in primary open-angle glaucoma or ocular hypertensive patients: a randomized clinical trial
por: Brant Fernandes RA, et al.
Publicado: (2019)

Intraocular pressure and visual field changes in normal-tension glaucoma patients treated using either unoprostone or latanoprost: a prospective comparative study
por: Takemoto D, et al.
Publicado: (2017)

Maximum Medical Therapy: Brinzolamide/Brimonidine And Travoprost/Timolol Fixed-Dose Combinations In Glaucoma And Ocular Hypertension
por: Lerner SF, et al.
Publicado: (2019)

Effect of preservative removal from fixed-combination bimatoprost/timolol on intraocular pressure lowering: a potential timolol dose–response phenomenon
por: Shen J, et al.
Publicado: (2016)

Ocular hypotensive effects of a Rho-associated protein kinase inhibitor in rabbits
por: Kamaruddin MI, et al.
Publicado: (2017)

Stratification-Based Investigation of Adjunctive Brimonidine or Timolol to a Prostaglandin Analogue in Japanese Patients with Normal-Tension Glaucoma
por: Yoshikawa K, et al.
Publicado: (2021)

Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients
por: Ruangvaravate N, et al.
Publicado: (2020)

Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction
por: Beck DER, et al.
Publicado: (2017)

Short-Term Efficacy and Safety of Switching from a Latanoprost/Timolol Fixed Combination to a Latanoprost/Carteolol Fixed Combination
por: Inoue K, et al.
Publicado: (2020)

Efficacy and safety of tafluprost 0.0015% – retrospective analysis of real-world data from the Philippines
por: Tumbocon JA, et al.
Publicado: (2019)

Dermoscopic Evaluation of Infantile Hemangioma Treated With Topical Timolol
por: Rubina Jassi, et al.
Publicado: (2020)

Comparative Study between Topical Latanoprost versus Topical 5- Fluorouracil after Dermabrasion for Treatment of Non-Segmental Stable Vitiligo
por: Rehab Abd El Razek, et al.
Publicado: (2021)

Physiochemical Properties and Cytotoxicity of a Benzalkonium Chloride-Free, Micellar Emulsion Ophthalmic Formulation of Latanoprost
por: Halder A, et al.
Publicado: (2020)

Clinical Evaluation of a Novel Electromechanical Topical Ocular Drug Delivery System: Two Phase 1 Proof of Concept Studies
por: Quiroz-Mercado H, et al.
Publicado: (2020)

Efficiency, safety, and patient preference of switching from dorzolamide 1%/timolol 0.5% to brinzolamide 1%/timolol 0.5% while maintaining the prostaglandin F2α analog
por: Shimizu Y, et al.
Publicado: (2015)

Active Pharmacovigilance in Peruvian Population: Surveillance of a Timolol/Brimonidine/Dorzolamide Ophthalmic Fixed Combination
por: Contreras-Salinas H, et al.
Publicado: (2021)

Prostaglandin-associated periorbitopathy in latanoprost users
por: Nakakura S, et al.
Publicado: (2014)

Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study
por: Economou MA, et al.
Publicado: (2018)

Latanoprost with high precision, piezo-print microdose delivery for IOP lowering: clinical results of the PG21 study of 0.4 µg daily microdose
por: Pasquale LR, et al.
Publicado: (2018)

Effect of prophylactic timolol 0.1% gel on intraocular pressure after an intravitreal injection of ranibizumab: a randomized study
por: Pece A, et al.
Publicado: (2016)

Efficacy Evaluation of 755-nm Long-Pulse Alexandrite Laser Combined with 0.5% Timolol Maleate Eye Drops in the Treatment of Thicker Infantile Hemangioma
por: Wu J, et al.
Publicado: (2021)

Efficacy and tolerability of brinzolamide/brimonidine suspension and prostaglandin analogs in patients previously treated with dorzolamide/timolol solution and prostaglandin analogs
por: Lo JS, et al.
Publicado: (2016)

Real-World Study on Patient Satisfaction and Tolerability After Switching to Preservative-Free Latanoprost
por: Erb C, et al.
Publicado: (2021)

Comparison between bimatoprost and latanoprost-timolol fixed combination for efficacy and safety after switching patients from latanoprost
por: Maruyama Y, et al.
Publicado: (2015)

Topical Medication Therapy for Glaucoma and Ocular Hypertension
por: Tao Wang, et al.
Publicado: (2021)

Efficacy of preservative-free tafluprost in patients with normal-tension glaucoma previously treated with latanoprost
por: Sacchi M, et al.
Publicado: (2014)

Comparison of the Intraocular Pressure-Lowering Efficacy and Safety of the Brinzolamide/Brimonidine Fixed-Dose Combination versus Concomitant Use of Brinzolamide and Brimonidine for Management of Open-Angle Glaucoma or Ocular Hypertension
por: Wang N, et al.
Publicado: (2020)

Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from latanoprost 0.005% monotherapy
por: Inoue K, et al.
Publicado: (2012)

Treatment persistence and cost-effectiveness of latanoprost/latanoprost&ndash;timolol, bimatoprost/bimatoprost&ndash;timolol, and travoprost/travoprost&ndash;timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database
por: Antoine Lafuma, et al.
Publicado: (2011)

Icare® rebound tonometers: review of their characteristics and ease of use
por: Nakakura S
Publicado: (2018)